CN111499567A - 一种马来酸氯苯那敏、其制备方法及应用 - Google Patents
一种马来酸氯苯那敏、其制备方法及应用 Download PDFInfo
- Publication number
- CN111499567A CN111499567A CN202010340632.8A CN202010340632A CN111499567A CN 111499567 A CN111499567 A CN 111499567A CN 202010340632 A CN202010340632 A CN 202010340632A CN 111499567 A CN111499567 A CN 111499567A
- Authority
- CN
- China
- Prior art keywords
- kettle
- feed liquid
- filter pressing
- pressing
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 title claims abstract description 82
- 229940046978 chlorpheniramine maleate Drugs 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 36
- 238000010438 heat treatment Methods 0.000 claims abstract description 35
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000010992 reflux Methods 0.000 claims abstract description 25
- 238000003756 stirring Methods 0.000 claims abstract description 25
- 229960003291 chlorphenamine Drugs 0.000 claims abstract description 15
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 14
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims abstract description 14
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 13
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 13
- 239000011976 maleic acid Substances 0.000 claims abstract description 13
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000000746 purification Methods 0.000 claims abstract description 8
- 238000001291 vacuum drying Methods 0.000 claims abstract description 7
- 238000005119 centrifugation Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 98
- 238000003825 pressing Methods 0.000 claims description 98
- 238000002425 crystallisation Methods 0.000 claims description 52
- 239000000047 product Substances 0.000 claims description 51
- 230000008025 crystallization Effects 0.000 claims description 48
- 239000002244 precipitate Substances 0.000 claims description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 238000001816 cooling Methods 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 239000000413 hydrolysate Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000011010 flushing procedure Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 9
- 239000002904 solvent Substances 0.000 abstract description 7
- 238000009776 industrial production Methods 0.000 abstract description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 2
- 238000011085 pressure filtration Methods 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 description 18
- 229910001220 stainless steel Inorganic materials 0.000 description 13
- 239000010935 stainless steel Substances 0.000 description 13
- 239000011521 glass Substances 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000007689 inspection Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- XSVWMIMFDMJQRL-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]pyridine Chemical compound C1=CC(Cl)=CC=C1CC1=CC=CC=N1 XSVWMIMFDMJQRL-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- QLSJOGIENLKPTF-BTJKTKAUSA-N (z)-but-2-enedioic acid;pyridine Chemical compound C1=CC=NC=C1.OC(=O)\C=C/C(O)=O QLSJOGIENLKPTF-BTJKTKAUSA-N 0.000 description 1
- IVYMIRMKXZAHRV-UHFFFAOYSA-N 4-chlorophenylacetonitrile Chemical compound ClC1=CC=C(CC#N)C=C1 IVYMIRMKXZAHRV-UHFFFAOYSA-N 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- QLKISOCKGGPANH-UHFFFAOYSA-N acetonitrile;chlorobenzene Chemical compound CC#N.ClC1=CC=CC=C1 QLKISOCKGGPANH-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010340632.8A CN111499567A (zh) | 2020-04-26 | 2020-04-26 | 一种马来酸氯苯那敏、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010340632.8A CN111499567A (zh) | 2020-04-26 | 2020-04-26 | 一种马来酸氯苯那敏、其制备方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111499567A true CN111499567A (zh) | 2020-08-07 |
Family
ID=71867958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010340632.8A Pending CN111499567A (zh) | 2020-04-26 | 2020-04-26 | 一种马来酸氯苯那敏、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111499567A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB834984A (en) * | 1958-03-04 | 1960-05-18 | Scherico Ltd | Optically active aryl-(2-pyridyl) aryl-substituted tertiary amines |
CN106883167A (zh) * | 2015-12-16 | 2017-06-23 | 张燕梅 | 一种新的马来酸氯苯那敏合成方法 |
CN110343108A (zh) * | 2019-08-13 | 2019-10-18 | 上海万巷制药有限公司 | 一种茶苯海明的合成方法 |
CN110372578A (zh) * | 2019-05-31 | 2019-10-25 | 嘉实(湖南)医药科技有限公司 | 一种新的马来酸氯苯那敏合成方法 |
-
2020
- 2020-04-26 CN CN202010340632.8A patent/CN111499567A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB834984A (en) * | 1958-03-04 | 1960-05-18 | Scherico Ltd | Optically active aryl-(2-pyridyl) aryl-substituted tertiary amines |
CN106883167A (zh) * | 2015-12-16 | 2017-06-23 | 张燕梅 | 一种新的马来酸氯苯那敏合成方法 |
CN110372578A (zh) * | 2019-05-31 | 2019-10-25 | 嘉实(湖南)医药科技有限公司 | 一种新的马来酸氯苯那敏合成方法 |
CN110343108A (zh) * | 2019-08-13 | 2019-10-18 | 上海万巷制药有限公司 | 一种茶苯海明的合成方法 |
Non-Patent Citations (1)
Title |
---|
陆嫣等: "《有机化学实验》", 30 June 2017 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101967145B (zh) | 一种抗血栓药物阿匹沙班的制备方法 | |
CN106905314A (zh) | 用于制备取代的5‑氟‑1h‑吡唑并吡啶类化合物的方法 | |
CN104945299B (zh) | 一种维格列汀的高效合成方法 | |
CN112358451B (zh) | 羧胺三唑的合成方法 | |
CN105085373B (zh) | 一种对阿普斯特产品的纯化方法 | |
CN105294496A (zh) | 一种西酞普兰中间体的制备方法 | |
JP7274000B2 (ja) | ペラミビル三水和物の新規な製造方法及びその水系乾燥 | |
CN106632137A (zh) | 氨噻肟酸乙酯的制备方法 | |
CN108440447A (zh) | 1,2,3,4-苯并噁三嗪-1,1(2h)-二氧化物的制备方法 | |
CN111499567A (zh) | 一种马来酸氯苯那敏、其制备方法及应用 | |
CN112457270A (zh) | 一种二氯五氯甲基噻唑制备方法 | |
CN107759519B (zh) | 一种塞来昔布杂质b的制备方法 | |
CN106810554A (zh) | 一种他达拉非化合物的制备方法 | |
CN113292513B (zh) | 一种高纯度盐酸异丙嗪的制备方法 | |
CN111362886A (zh) | 一种泊沙康唑中间体1-(4-氨基苯基)-4-(4-羟基苯基)哌嗪的制备方法 | |
CN114105872B (zh) | 一种用于制备盐酸丙卡特罗的中间体及其制备方法 | |
CN106008364A (zh) | 一种selexipag的制备方法 | |
JP7407215B2 (ja) | 4-(パーフルオロプロパン-2-イル)-2-トリフルオロメチルアニリンの調製方法およびその使用 | |
CN111393357A (zh) | 一种马来酸氯苯那敏的精制方法 | |
CN111285821A (zh) | 一种连续制备非布司他的方法 | |
CN114195712B (zh) | 一种能够用来制备盐酸丙卡特罗的中间体及其制备方法 | |
CN115960059A (zh) | 一种高产率高纯度合成呋塞米杂质d的方法 | |
CN111533686A (zh) | 一种马来酸氯苯那敏成盐物、其合成方法及应用 | |
CN104829571B (zh) | 草酸艾司西酞普兰相关物质及其制备方法 | |
CN113045468A (zh) | 一种布瓦西坦中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Qing Wenbin Inventor after: Zhao Jianhong Inventor after: Bai Ting Inventor after: Zhou Qiuhuo Inventor after: Hua Jitao Inventor after: Jin Fang Inventor before: Qing Wenbin Inventor before: Bai Ting Inventor before: Zhou Qiuhuo Inventor before: Hua Jitao Inventor before: Jin Fang |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200807 |